BioWorld MedTech

Dec. 9, 2014

Edwards hoping for early 2016 approval of Sapien 3 Transcatheter Heart Valve

An FDA approval for Edwards Lifesciences' (Irvine, California) Sapien 3 Transcatheter Heart Valve could come in early 2016, the company said in an investor's call on Monday. Original expectations for FDA approval were estimated for mid-2016. Read More

Asia in the Spotlight: Japan cautiously optimistic about use of medical robots

Report from Canada: Getting tough on post-market medical device performance

Inside the Beltway: AHRQ; hospital-acquired conditions down by 50,000 from 2010 to 2013

Financings: CardioKinetix completes $50 million financing led by Edwards Lifesciences

Agreements/contracts: Orthocell partners with Bone Support to advance bone repair

Hit Bits: Qualcomm collaborates with Vitaphone e-health solutions

Court Report: Stryker pleads guilty to selling unapproved devices, to pay $80M

Product briefs

People in Places

MDD's Craiology Extra

Today's news in brief

BioWorld

BioWorld briefs for Nov. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 27, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...